The rationale behind the treatment is that, because genetic FXI deficiency has been linked with reduced risk of ischemic ...
Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...
Global phase 3 OCEANIC-STROKE randomized 12,327 patients to asundexian 50 mg daily vs placebo on background antiplatelets, with follow-up to 31 months. Treatment effects were consistent across TOAST ...
Bayer is vying to be first to market in the oral Factor XIa category against Bristol Myers Squibb and Johnson & Johnson, ...
— Company now expects to complete enrollment of 150 patients in Q2 2026, with a Phase 3 data readout in mid-2027; Rolling NDA submission planned to initiate in first half 2027— — Discussions with FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results